Voices
Paolo Tarantino
Paolo Tarantino/X

Paolo Tarantino: Can We Combine Radiotherapy with CDK4/6i, HER2, PARP or mTOR Targeted Agents?

Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on LinkedIn:

“Can we combine radiotherapy with CDK4/6i, HER2, PARP or mTOR targeted agents?

Just out on the green journal the ESMO-ESTRO systematic review (107 studies) and Delphi consensus on the topic.

Huge work, masterfully led by Evert van Aken.”

Title: ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors

Authors: Evert van Aken, Ajeet Kumar Gandhi, Sean O’Cathail, Gerben Borst, Jorge Barriuso, Emmanouil Fokas, Luis Castelo-Branco, Anne Hansen Reek, Evandro de Azambuja, Stephanie Kroezem, Ilaria Colombo, Antonin Levy, Carmen Criscitiello, Maximilian Niyazi, Nadia Harbeck, Ewa Szutowicz, Gabor Liposits, Marcel Verheij, Isabelle Ray-Coquard, Paolo Tarantino, Dario Trapani, Paulien Boot, Claus Belka, Dirk De Ruysscher, George Pentheroudakis, Corrie Marijnen, Florian Lordick, Umberto Ricardi, Diogo Martins-Branco, Arsela Prelaj, Monique de Jong, Bharti Devnani

Read the Full Article.

Paolo Tarantino: Can We Combine Radiotherapy with CDK4/6i, HER2, PARP or mTOR Targeted Agents?

More posts featuring Paolo Tarantino on OncoDaily.

Ajeet Kumar Gandhi Anne Hansen Reek Antonin Levy Arsela Prelaj Bharti Devnani cancer carmen criscitiello Claus Belka Corrie Marijnen Dario Trapani Diogo Martins Branco Dirk de Ruysscher Emmanouil Fokas Evandro de Azambuja Evert van Aken Ewa Szutowicz Florian Lordick Gabor Liposits George Pentheroudakis Gerben Borst Ilaria Colombo Isabelle Ray-Coquard Jorge Barriuso Luis Castelo-Branco Marcel Verheij Maximilian Niyazi Monique de Jong Nadia Harbeck OncoDaily Oncology Paolo Tarantino Paulien Boot radiotherapy Sean O’Cathail Stephanie Kroezem Umberto Ricardi